CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
68Ga PSMA-11 injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04179968
NCT04179968Phase 2Completed
CompareCT.gov

The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer

Dana Mathews·interventional·Posted Nov 27, 2019·Updated Mar 20, 2023

In Brief

A Phase 2 clinical trial evaluating 68Ga PSMA-11 injection and Positron Emission Tomography/Computed Tomography for Prostate Cancer and Prostate Cancer Metastatic. Completed, enrolled 20 participants across 1 site.

Detailed Summary

To goal of this research is to assess the ability of Gallium-68 (68Ga) Prostate-Specific Membrane Antigen-11 (PSMA-11) positron emission tomography/computed tomography (PET/CT) to increase diagnostic accuracy in localizing primary and metastatic lesions in patients with suspected prostate cancer and elevated Prostate Imaging Reporting and Data System (PI-RADS) scores and Prostate-Specific Antigen (PSA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Prostate Cancer Metastatic
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedNov 27, 2019
Enrollment StartJan 27, 2020
Primary CompletionSep 9, 2021
Study CompletionJul 15, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.6 years ago

Interventions

68Ga PSMA-11 injectiondrug

Injection of 68Ga PSMA-11

Positron Emission Tomography/Computed Tomographyprocedure

PET/CT scan after 68Ga PSMA-11 injection